Quality of life after breast-conserving surgery for women with non-low-risk ductal carcinoma in situ

Affiliations

¹ Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, UK; School of Medicine, Anglia Ruskin University, Cambridge, UK; School of Medicine, Anglia Ruskin University, Chelmsford, UK. Electronic address: john.benson@addenbrookes.nhs.uk.

Comment

John R Benson. Lancet Oncol. 2020 May.

. 2020 May;21(5):612-614.

doi: 10.1016/S1470-2045(20)30135-2. Epub 2020 Mar 20.

¹ Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, UK; School of Medicine, Anglia Ruskin University, Cambridge, UK; School of Medicine, Anglia Ruskin University, Chelmsford, UK. Electronic address: john.benson@addenbrookes.nhs.uk.

No abstract available

Comment on

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH; BIG 3-07/TROG 07.01 trial investigators. King MT, et al. Lancet Oncol. 2020 May;21(5):685-698. doi: 10.1016/S1470-2045(20)30085-1. Epub 2020 Mar 20. Lancet Oncol. 2020. PMID: 32203696 Clinical Trial.